Login with Linked

Follow us on

Link Linkedin Youtube

Iqirvo

Iqirvo is used with ursodeoxycholic acid to treat primary biliary cholangitis. It works by targeting key pathways in the liver, including PPAR alpha and PPAR delta.

Molecule Details :

  • Molecule Name :

    Elafibranor

  • Innovator :

    IPSEN BIOPHARMACEUTICALS INC

  • Approval Date :

    10-Jun-24

  • NCE-1 Date :

    10-Jun-28

  • NCE Date :

    10-Jun-29

  • Dosage Form :

    Oral Tablets

  • Strength :

    80MG

  • Therapeutic Category :

    Hepatoprotective Agents

  • Revenue ($M) :

    24

Year-wise Projected Sales ($M) :

  • 2025 :

    137

  • 2026 :

    242

  • 2027 :

    353

  • 2028 :

    436

  • 2029 :

    515

  • 2030 :

    593

  • 2031 :

    649
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?